ArticleCancer causes & control : CCC2019
Non-alcoholic fatty liver disease and colorectal cancer survival.
Article in Cancer causes & control : CCC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Pooled it
- The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2022Pooled it
- From steatosis to metastasis: microenvironmental reprogramming of the liver in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Liver fat and clinical outcomes in individuals with stage I-III colon or rectal cancer.Journal of the National Cancer Institute · 2026Article
- Assessment of the correlation between visceral adiposity and liver fat in metastatic colorectal cancer patients.International journal of colorectal disease · 2025Article
- The newly proposed dietary index for gut microbiota and its association with the risk of nonalcoholic fatty liver disease: the mediating role of body mass index.Diabetology & metabolic syndrome · 2025Article
- Metastatic tumor growth in steatotic liver is promoted by HAS2-mediated fibrotic tumor microenvironment.The Journal of clinical investigation · 2025Article
- Unveiling the cancer risk nexus of the steatotic liver.Trends in endocrinology and metabolism: TEM · 2024Review
- Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD.Molecules and cells · 2024Review
- New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk.JAMA network open · 2023Article
- Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment.Cell metabolism · 2023Article
- Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration.Nutrients · 2022Review
- Biodistribution and Activity of EGFR Targeted Polymeric Micelles Delivering a New Inhibitor of DNA Repair to Orthotopic Colorectal Cancer Xenografts with Metastasis.Molecular pharmaceutics · 2022Article
- The molecular basis of the associations between non-alcoholic fatty liver disease and colorectal cancer.Frontiers in genetics · 2022Article
- Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?Clinical liver disease · 2021Review
- Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links.Life sciences · 2020Review
- Liver imaging features by convolutional neural network to predict the metachronous liver metastasis in stage I-III colorectal cancer patients based on preoperative abdominal CT scan.BMC bioinformatics · 2020Article
- Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.Hepatology international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeLiver diseases including non-alcoholic fatty liver disease (NAFLD) and ensuing alterations to the micro-environment may affect development of liver metastasis. Mirroring the rise in obesity rates, prevalence of NAFLD is increasing globally. Our objective was to examine the association between NAFLD and mortality in colorectal cancer patients.
methodsColorectal Cancer-Sarcopenia and Near-term Survival (C-SCANS) is a retrospective cohort study which included 3,262 stage I-III patients, aged 18-80 years, and diagnosed between 2006 and 2011 at Kaiser Permanente Northern California. Cox proportional hazards regression was used to calculate multivariable adjusted hazard ratios (HR) and 95% confidence intervals (CI).
resultsAfter up to 10 years of follow-up, 879 deaths, including 451 from CRC were identified. Cases diagnosed with NAFLD before and within 1 month after CRC diagnosis (pre-existing NAFLD; n = 83) had a HR of 1.64 (95% CI 1.06-2.54) for overall and a HR of 1.85 (95% CI 1.03-3.30) for CRC-specific mortality compared to those without NAFLD. Findings did not differ significantly by sex, stage, tumor location, and smoking status, and were also similar when restricted to obese patients only.
conclusionsIndependent of body mass index and prognostic indicators, CRC patients with pre-existing NAFLD had a worse prognosis than those without NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.